Why the study?
Does acetylcysteine prevent acute doxorubicin-induced myocardial morphologic damage in patients with normal cardiovascular function?
Does acetylcysteine prevent acute doxorubicin-induced myocardial morphologic damage in patients with normal cardiovascular function?
Prophylactic administration of acetylcysteine does not prevent acute doxorubicin-induced myocardial morphologic damage.
Answers are grounded in this paper and cite their sources.
Acetylcysteine should not be used to prevent acute doxorubicin myocardial damage; confirms null effect on morphology in RCT.
Doxorubicin induced acute as well as chronic myocardial morphologic alterations. Twenty patients with normal cardiovascular function were randomized to 2 groups based on age and dose of doxorubicin. Group I received placebo 1 hour before doxorubicin administration; group II received acetylcysteine (N-acetyl-L-cysteine) (Nac) 1 hour before doxorubicin. Endomyocardial biopsies were performed at base line at 4 and 24 hours after doxorubicin administration. Biopsy tissue was viewed by electron microscopy, and stereoscopic techniques were used to determine tubular and mitochondrial area. The change of the tubular area was similar in the 2 groups, was maximum at 4 hours, and was proportionately spread throughout the cell. The mitochondrial swelling was also similar in the 2 groups and proportionate throughout the cell but was maximum at 24 hours. This study demonstrated that the acute doxorubicin-induced damage was diffuse and not prevented by Nac.
No takes yet. Share an insight, caveat, or question.
Unverferth et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: